{"id":26074,"date":"2024-07-01T09:34:05","date_gmt":"2024-07-01T07:34:05","guid":{"rendered":"https:\/\/idibell.cat\/?p=26074"},"modified":"2024-07-01T10:44:07","modified_gmt":"2024-07-01T08:44:07","slug":"descobreixen-biomarcadors-que-prediuen-la-resposta-a-la-immunoterapia-en-el-carcinoma-de-pell","status":"publish","type":"post","link":"https:\/\/idibell.cat\/2024\/07\/descobreixen-biomarcadors-que-prediuen-la-resposta-a-la-immunoterapia-en-el-carcinoma-de-pell\/","title":{"rendered":"Descobreixen biomarcadors que prediuen la resposta a la immunoter\u00e0pia en el carcinoma de pell"},"content":{"rendered":"

El carcinoma de c\u00e8l\u00b7lules escamoses de la pell \u00e9s el segon c\u00e0ncer de pell m\u00e9s freq\u00fcent i es preveu que en els propers anys augmentin els nous casos diagnosticats. Encara que en la majoria de casos l’escissi\u00f3 quir\u00fargica \u00e9s suficient, alguns pacients acaben desenvolupant tumors agressius amb un pron\u00f2stic cl\u00ednic desfavorable. Per a aquests, la <\/span>immunoter\u00e0pia anti-PD-1<\/span><\/b> ha suposat un aven\u00e7 terap\u00e8utic important, ja que aquests f\u00e0rmacs potencien l’activitat antitumoral del sistema immunitari del pacient. Malgrat aix\u00f2, encara no se sap de forma precisa perqu\u00e8 prop de la meitat dels pacients no responen o b\u00e9 adquireixen resist\u00e8ncia al tractament. Aix\u00f2 fa prioritari trobar <\/span>biomarcadors que ajudin a identificar i seleccionar els pacients que es beneficiaran m\u00e9s del tractament<\/span><\/b>.<\/span>\u00a0<\/span><\/p>\n

Aquest ha estat l’objectiu de l’estudi publicat a la revista <\/span>Nature Communications<\/span><\/i> i liderat per les <\/span>Dres. Laura Lorenzo-Sanz<\/span><\/b>, tamb\u00e9 primera autora del treball, i <\/span>Purificaci\u00f3n Mu\u00f1oz<\/span><\/b>, cap del grup d’envelliment i c\u00e0ncer de l’IDIBELL. Amb la col\u00b7laboraci\u00f3 d’altres institucions, com l’ICO i l’Hospital de Bellvitge, els investigadors han pogut <\/span>descriure com les c\u00e8l\u00b7lules tumorals d’aquest carcinoma interactuen i bloquegen l’acci\u00f3 del sistema immunitari<\/span><\/b> en els diferents moments de la progressi\u00f3 tumoral, adaptant-se de forma din\u00e0mica i pl\u00e0stica, el qual permet identificar els <\/span>tractaments m\u00e9s efica\u00e7os per a cada estadi de la malaltia<\/span><\/b>.<\/span>\u00a0<\/span><\/p>\n

\u201c<\/span>Hem trobat <\/span><\/i>biomarcadors que prediuen la resposta del tumor a la immunoter\u00e0pia en diferents estadis de progressi\u00f3<\/span><\/i><\/b>, utilitzant mostres de carcinoma de c\u00e8l\u00b7lules escamoses de la pell, cap i coll, i de melanoma. Aquests biomarcadors permetrien predir la resposta a la immunoter\u00e0pia anti-PD-1 i ens informarien de quina opci\u00f3 terap\u00e8utica seria la m\u00e9s apropiada per a cada pacient<\/span><\/i>\u201d, comenta la <\/span>Dra. Mu\u00f1oz<\/span><\/b>.<\/span>\u00a0<\/span><\/p>\n

En conclusi\u00f3 i com explica la <\/span>Dra. Lorenzo-Sanz<\/span><\/b>, \u201c<\/span>Aquests resultats s\u00f3n prometedors i confiem que, un cop validades les conclusions en un nombre m\u00e9s gran de pacients, puguem arribar a <\/span><\/i>personalitzar l\u2019estrat\u00e8gia terap\u00e8utica m\u00e9s adequada per cada pacient<\/span><\/i><\/b> i aix\u00ed augmentar la seva esperan\u00e7a i qualitat de vida<\/span><\/i>\u201d.<\/span>\u00a0<\/span><\/p>\n

\u00a0<\/span><\/p>\n

 <\/p>\n

L\u2019Institut d’Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL) \u00e9s un centre de recerca en biomedicina creat l\u2019any 2004. Est\u00e0 participat per l’Hospital Universitari de Bellvitge i l\u2019Hospital de Viladecans de l’Institut Catal\u00e0 de la Salut, l’Institut Catal\u00e0 d’Oncologia, la Universitat de Barcelona i l\u2019Ajuntament de l\u2019Hospitalet de Llobregat.<\/span><\/i>\u00a0<\/span><\/p>\n

L\u2019IDIBELL \u00e9s membre del Campus d’Excel\u00b7l\u00e8ncia Internacional de la Universitat de Barcelona HUBc i forma part de la instituci\u00f3 CERCA de la Generalitat de Catalunya. L’any 2009 es va convertir en un dels cinc primers centres d\u2019investigaci\u00f3 espanyols acreditats com a institut d\u2019investigaci\u00f3 sanit\u00e0ria per l\u2019Instituto de Salud Carlos III. A m\u00e9s, forma part del programa \u201cHR Excellence in Research\u201d de la Uni\u00f3 Europea i \u00e9s membre de EATRIS i REGIC. Des de l\u2019any 2018, l\u2019IDIBELL \u00e9s un Centro Acreditado de la Fundaci\u00f3n Cient\u00edfica AECC (FCAECC).<\/span><\/i><\/p>\n","protected":false},"excerpt":{"rendered":"

Investigadors de l’IDIBELL han descobert un mecanisme pel qual les c\u00e8l\u00b7lules tumorals responen diferent a diverses immunoter\u00e0pies i han identificat biomarcadors que poden predir la resposta a aquests f\u00e0rmacs. Publicat a Nature Communications, aquesta troballa permetr\u00e0 personalitzar el tractament del carcinoma de pell i aix\u00ed augmentar la qualitat de la vida dels pacients.<\/p>\n","protected":false},"author":8,"featured_media":26075,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"set","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[332,357,447],"tags":[],"class_list":["post-26074","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cancer","category-envelliment-i-cancer","category-p-de-mecanismes-molelculars-i-terapia-experimental-en-oncologia-oncobell"],"publishpress_future_action":{"enabled":false,"date":"2024-12-29 08:14:46","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category"},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/26074","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/comments?post=26074"}],"version-history":[{"count":3,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/26074\/revisions"}],"predecessor-version":[{"id":26078,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/26074\/revisions\/26078"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media\/26075"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media?parent=26074"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/categories?post=26074"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/tags?post=26074"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}